NCT02371499View on ClinicalTrials.gov

Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

Lactobacillus casei DG

the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks

DIETARY_SUPPLEMENT

Placebo

the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks

Trial Locations (5)

20097

Policlinico S.Donato, San Donato

40100

Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna

Unknown

U.O. Gastroenterologia Universitaria, Pisa

Azienda ULSS 1, Belluno

00128

Policlinico Universitario Campus Biomedico, Roma

All Listed Sponsors
lead

SOFAR S.p.A.

INDUSTRY

NCT02371499 - Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study | Biotech Hunter | Biotech Hunter